PBKM – EKF interview

Published on 20 October 2021

In this interview, CEO Jakub Baran discusses PBKM’s profile as a leading European stem cell bank. He outlines the recent voluntary exchange offer launched by Vita34 and PBKM’s strategy after the merger. He then explains the effect of COVID-19 on PBKM’s offline distribution channels and provides an update on the developments within PBKM’s therapies and drug manufacturing business.

Share this with friends and colleagues